跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
212Pb-PSMA
首页
药物
212Pb-PSMA
212Pb-PSMA
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Lead and thorium compounds
申请人: SCIENCONS AS
优先权: 2017
CN
US
WO
9 件公开
PSMA-TARGETING RADIOACTIVE METAL COMPLEX CONTAINING NITRO AROMATIC HETEROCYCLIC GROUP AND PREPARATION THEREOF
申请人: UNIV BEIJING NORMAL
优先权: 2023
CN
WO
2 件公开
COMPOUND FOR DUAL TARGETING OF TUMOR CELL, AND PREPARATION METHOD THEREFOR AND USE THEREOF
申请人: PEKING UNION MEDICAL COLLEGE HOSPITAL CAMS
优先权: 2024
CN
WO
2 件公开
Labeled inhibitors of prostate-specific membrane antigen (PSMA), their use as imaging agents and agents for treatment of PSMA-expressing cancers
申请人: UNIV HEIDELBERG
优先权: 2018
CN
Application of 212Pb-EB-PSMA-617 in prostate cancer
申请人: BEIJING SINOTAU PHARMACEUTICALS CO LTD
优先权: 2023
CN
药物
反馈